RAJAF TFA Therapeutics, Inc. OTC · United States

TFA Therapeutics (RAJAF) news

TFA Therapeutics, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker RAJAF, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest TFA Therapeutics news

We have not published a story on TFA Therapeutics yet. When there is news, it will appear here.

TFA Therapeutics annual financials

Line	FY2025	FY2024
Revenue	$1.2 million	$1.3 million
Net income (loss)	-$154,822	-$226,258
Cash from operations	-$35,845	$312,006
Cash and equivalents	$3,199	$37,284

Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $3,199.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about TFA Therapeutics

What is the ticker symbol of TFA Therapeutics?

TFA Therapeutics, Inc. trades under the ticker RAJAF on OTC.

Where is TFA Therapeutics listed?

TFA Therapeutics, Inc. is listed on OTC.

Which country or territory is TFA Therapeutics listed under?

Our directory records TFA Therapeutics, Inc. under United States.

Does aibio.space cover TFA Therapeutics?

aibio.space lists TFA Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was TFA Therapeutics's revenue last year?

$1.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is TFA Therapeutics profitable?

TFA Therapeutics, Inc. reported a net loss of $154,822 for the fiscal year ended Dec 31, 2025, and used $35,845 of cash in operations, per its annual report to the SEC.

How much cash does TFA Therapeutics have?

$3,199 in cash at Dec 31, 2025, per its 20-F.

Investor discussion: TFA Therapeutics

Members talk about TFA Therapeutics (RAJAF). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at TFA Therapeutics, newest first. Each line links the filing it comes from.

Sep 2, 2026Financings
Reported a financing. SEC Form 6-K. Source
Apr 30, 2026Distress
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:RAJAF on TradingView.

Listing details

Company: TFA Therapeutics, Inc.
Ticker: RAJAF
Listing: OTC
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction